Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients

BACKGROUND: In the double-blind, phase 3 PALOMA-3 study, palbociclib–fulvestrant significantly prolonged progression-free survival versus placebo–fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer (MBC) who...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Clin Oncol
Autors principals: Masuda, Norikazu, Inoue, Kenichi, Nakamura, Rikiya, Rai, Yoshiaki, Mukai, Hirofumi, Ohno, Shinji, Hara, Fumikata, Mori, Yuko, Hashigaki, Satoshi, Muramatsu, Yasuaki, Nagasawa, Takashi, Umeyama, Yoshiko, Huang, Xin, Iwata, Hiroji
Format: Artigo
Idioma:Inglês
Publicat: Springer Singapore 2018
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6399170/
https://ncbi.nlm.nih.gov/pubmed/30392115
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10147-018-1359-3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars